PURPOSE: We previously reported a randomized phase II clinical trial combining a poxvirus-based vaccine encoding prostate-specific antigen (PSA) with radiotherapy in patients with localized prostate cancer. Here, we investigate whether vaccination against PSA induced immune responses to additional tumor-associated antigens and how this influenced clinical outcome. EXPERIMENTAL DESIGN: Pretreatment and posttreatment serum samples from patients treated with vaccine + external beam radiation therapy (EBRT) versus EBRT alone were evaluated by Western blot and serologic screening of a prostate cancer cDNA expression library (SEREX) to assess the development of treatment-associated autoantibody responses. RESULTS: Western blotting revealed treatment-associated autoantibody responses in 15 of 33 (45.5%) patients treated with vaccine + EBRT versus 1 of 8 (12.5%) treated with EBRT alone. SEREX screening identified 18 antigens, which were assembled on an antigen array with 16 previously identified antigens. Antigen array screening revealed that 7 of 33 patients (21.2%) treated with vaccine + EBRT showed a vaccine-associated autoantibody response to four ubiquitously expressed self-antigens: DIRC2, NDUFS1, MRFAP1, and MATN2. These responses were not seen in patients treated with EBRT alone, or other control groups. Patients with autoantibody responses to this panel of antigens had a trend toward decreased biochemical-free survival. CONCLUSIONS: Vaccine + EBRT induced antigen spreading in a large proportion of patients. A subset of patients developed autoantibodies to a panel of four self-antigens and showed a trend toward inferior outcomes. Thus, cancer vaccines directed against tumor-specific antigens can trigger autoantibody responses to self-proteins, which may influence the efficacy of vaccination. (c) 2010 AACR.
PURPOSE: We previously reported a randomized phase II clinical trial combining a poxvirus-based vaccine encoding prostate-specific antigen (PSA) with radiotherapy in patients with localized prostate cancer. Here, we investigate whether vaccination against PSA induced immune responses to additional tumor-associated antigens and how this influenced clinical outcome. EXPERIMENTAL DESIGN: Pretreatment and posttreatment serum samples from patients treated with vaccine + external beam radiation therapy (EBRT) versus EBRT alone were evaluated by Western blot and serologic screening of a prostate cancer cDNA expression library (SEREX) to assess the development of treatment-associated autoantibody responses. RESULTS: Western blotting revealed treatment-associated autoantibody responses in 15 of 33 (45.5%) patients treated with vaccine + EBRT versus 1 of 8 (12.5%) treated with EBRT alone. SEREX screening identified 18 antigens, which were assembled on an antigen array with 16 previously identified antigens. Antigen array screening revealed that 7 of 33 patients (21.2%) treated with vaccine + EBRT showed a vaccine-associated autoantibody response to four ubiquitously expressed self-antigens: DIRC2, NDUFS1, MRFAP1, and MATN2. These responses were not seen in patients treated with EBRT alone, or other control groups. Patients with autoantibody responses to this panel of antigens had a trend toward decreased biochemical-free survival. CONCLUSIONS: Vaccine + EBRT induced antigen spreading in a large proportion of patients. A subset of patients developed autoantibodies to a panel of four self-antigens and showed a trend toward inferior outcomes. Thus, cancer vaccines directed against tumor-specific antigens can trigger autoantibody responses to self-proteins, which may influence the efficacy of vaccination. (c) 2010 AACR.
Authors: Craig L Slingluff; Gina R Petroni; Walter C Olson; Mark E Smolkin; Merrick I Ross; Naomi B Haas; William W Grosh; Marc E Boisvert; John M Kirkwood; Kimberly A Chianese-Bullock Journal: Clin Cancer Res Date: 2009-11-10 Impact factor: 12.531
Authors: James L Gulley; Philip M Arlen; Ravi A Madan; Kwong-Yok Tsang; Mary P Pazdur; Lisa Skarupa; Jacquin L Jones; Diane J Poole; Jack P Higgins; James W Hodge; Vittore Cereda; Matteo Vergati; Seth M Steinberg; Susan Halabi; Elizabeth Jones; Clara Chen; Howard Parnes; John J Wright; William L Dahut; Jeffrey Schlom Journal: Cancer Immunol Immunother Date: 2009-11-05 Impact factor: 6.968
Authors: Sarah E Church; Shawn M Jensen; Christopher G Twitty; Keith Bahjat; Hong-Ming Hu; Walter J Urba; Bernard A Fox Journal: Cancer J Date: 2011 Sep-Oct Impact factor: 3.360
Authors: Parmita Saxena; Marco Trerotola; Tao Wang; Jing Li; Aejaz Sayeed; Jennifer Vanoudenhove; Dave S Adams; Thomas J Fitzgerald; Dario C Altieri; Lucia R Languino Journal: Prostate Date: 2011-09-28 Impact factor: 4.104
Authors: Debraj GuhaThakurta; Nadeem A Sheikh; Li-Qun Fan; Harini Kandadi; T Craig Meagher; Simon J Hall; Philip W Kantoff; Celestia S Higano; Eric J Small; Thomas A Gardner; Kate Bailey; Tuyen Vu; Todd DeVries; James B Whitmore; Mark W Frohlich; James B Trager; Charles G Drake Journal: Clin Cancer Res Date: 2015-02-03 Impact factor: 12.531
Authors: Andrew B Sharabi; Phuoc T Tran; Michael Lim; Charles G Drake; Theodore L Deweese Journal: Oncology (Williston Park) Date: 2015-05 Impact factor: 2.990
Authors: James L Gulley; Ravi A Madan; Kwong Y Tsang; Caroline Jochems; Jennifer L Marté; Benedetto Farsaci; Jo A Tucker; James W Hodge; David J Liewehr; Seth M Steinberg; Christopher R Heery; Jeffrey Schlom Journal: Cancer Immunol Res Date: 2013-11-04 Impact factor: 11.151